NCT06436846 Genomic Risk in Retroperitoneal Sarcoma
| NCT ID | NCT06436846 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fox Chase Cancer Center |
| Condition | Retroperitoneal Liposarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-03-07 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-03-07 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.
Eligibility Criteria
Inclusion Criteria: * Adult patients (age ≥18 years). * Histologically confirmed retroperitoneal liposarcoma via preoperative biopsy, or cross-sectional imaging suspicious for liposarcoma with planned surgical resection * Will be undergoing surgical resection for treatment of primary or recurrent disease * Have provided informed consent to participate in this study Exclusion Criteria: • Prior surgical anatomy which makes sampling of remote areas of the retroperitoneum technically impossible or clinically undesirable for safety reasons
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06436846 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Retroperitoneal Liposarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06436846 currently recruiting?
Yes, NCT06436846 is actively recruiting participants. Contact the research team at anthony.villano@fccc.edu for enrollment information.
Where is the NCT06436846 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06436846 clinical trial?
NCT06436846 is sponsored by Fox Chase Cancer Center. The trial plans to enroll 50 participants.